The evolutionary landscape of SARS-CoV-2 variant B.1.1.519 and its clinical impact in Mexico City

Cedro‐Tanda, Alberto; Gómez-Romero, Laura; Alcaraz, Nicolás; Anda-Jáuregui, Guillermo de; Peñaloza, Fernando; Moreno, Bernardo; Escobar-Arrazola, Marco A.; Ramirez-Vega, Oscar A; Munguía-Garza, Paulina; Garcia-Cardenas, Francisco; Cisneros-Villanueva, Mireya; Moreno-Camacho, José L; Rodriguez-Gallegos, Jorge; Esparza, Marco A. Luna-Ruiz; Fernandez-Rojas, Miguel A; Mendoza-Vargas, Alfredo; Reyes‐Grajeda, Juan Pablo; Campos‐Romero, Abraham; Angulo, Ofelia; Ruiz, Rosaura; Sheinbaum-Pardo, Claudia; Sifuentes–Osornio, José; Hidalgo‐Miranda, Alfredo; Herrera, Luis A.

doi:10.1101/2021.09.07.21262911

Cited by 17 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an additional circumstance around the protocol, it is important to stress that the study was conducted almost concurrently with a COVID-19 wave in Mexico driven by the emergence of the B.1.617.2 (Delta) variant in Mexico City (34). This circumstance affected the clinical trial as some of the participants were infected either between the first and the second dose or after the administration of the second dose as reported in Table 4 .…”

Section: Methodsmentioning

confidence: 99%

“…Inactivated versions of the vaccine are currently in clinical development in Vietnam (NCT04830800), Brazil (NCT04993209) and Thailand (NCT04764422). Interim results from Thailand show that the inactivated formulation – which is injected intramuscularly -is safe and highly immunogenic (34). Here, we tested a live version of the vaccine, AVX/COVID-12-HEXAPRO (Patria, also known as NDV-HXP-S), in an open label non-randomized non-placebo-controlled phase I trial in 91 healthy volunteers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

Ponce-de-León

Torres

Soto-Ramírez

et al. 2022

Preprint

View full text Add to dashboard Cite

There is still a need for safe, efficient and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expresses a stable version of the spike protein in infected cells as well as on the surface of the viral particle (AVX/COVID-12-HEXAPRO, also known as NDV-HXP-S). This vaccine candidate can be grown in embryonated eggs at low cost similar to influenza virus vaccines and it can also be administered intranasally, potentially to induce mucosal immunity. We evaluated this vaccine candidate in prime-boost regimens via intramuscular, intranasal, or intranasal followed by intramuscular routes in an open label non-randomized non-placebo-controlled phase I clinical trial in Mexico in 91 volunteers. The primary objective of the trial was to assess vaccine safety and the secondary objective was to determine the immunogenicity of the different vaccine regimens. In the interim analysis reported here, the vaccine was found to be safe and the higher doses tested were found to be immunogenic when given intramuscularly or intranasally followed by intramuscular administration, providing the basis for further clinical development of the vaccine candidate. The study is registered under ClinicalTrials.gov identifier NCT04871737. Funding was provided by Avimex and CONACYT.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

Ponce-de-León

Torres

Soto-Ramírez

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…During the first wave of the COVID-19 pandemic, the predominant SARS-CoV-2 variants circulating in Mexico City were B.1, B.1.1, and B.1609, followed by an increase in the B.1.1.222, B.1.189, and B.1.241 (22). From January 2021 onward, variant 1.1.519 became dominant (23).…”

Section: Methodsmentioning

confidence: 99%

Outcomes in Temporary ICUs Versus Conventional ICUs: An Observational Cohort of Mechanically Ventilated Patients With COVID-19–Induced Acute Respiratory Distress Syndrome

Jiménez

Olivas-Martínez

Rios-Olais

et al. 2022

Critical Care Explorations

Self Cite

View full text Add to dashboard Cite

IMPORTANCE: Throughout the COVID-19 pandemic, thousands of temporary ICUs have been established worldwide. The outcomes and management of mechanically ventilated patients in these areas remain unknown. OBJECTIVES: To investigate mortality and management of mechanically ventilated patients in temporary ICUs. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study in a single-institution academic center. We included all adult patients with severe COVID-19 hospitalized in temporary and conventional ICUs for invasive mechanical ventilation due to acute respiratory distress syndrome from March 23, 2020, to April 5, 2021. MAIN OUTCOMES AND MEASURES: To determine if management in temporary ICUs increased 30-day in-hospital mortality compared with conventional ICUs. Ventilator-free days, ICU-free days (both at 28 d), hospital length of stay, and ICU readmission were also assessed. RESULTS: We included 776 patients (326 conventional and 450 temporary ICUs). Thirty-day in-hospital unadjusted mortality (28.8% conventional vs 36.0% temporary, log-rank test p = 0.023) was higher in temporary ICUs. After controlling for potential confounders, hospitalization in temporary ICUs was an independent risk factor associated with mortality (hazard ratio, 1.4; CI, 1.06–1.83; p = 0.016).There were no differences in ICU-free days at 28 days (6; IQR, 0–16 vs 2; IQR, 0–15; p = 0.5) or ventilator-free days at 28 days (8; IQR, 0–16 vs 5; IQR, 0–15; p = 0.6). We observed higher reintubation (18% vs 12%; p = 0.029) and readmission (5% vs 1.6%; p = 0.004) rates in conventional ICUs despite higher use of postextubation noninvasive mechanical ventilation (13% vs 8%; p = 0.025). Use of lung-protective ventilation (87% vs 85%; p = 0.5), prone positioning (76% vs 79%; p = 0.4), neuromuscular blockade (96% vs 98%; p = 0.4), and COVID-19 pharmacologic treatment was similar. CONCLUSIONS AND RELEVANCE: We observed a higher 30-day in-hospital mortality in temporary ICUs. Although both areas had high adherence to evidence-based management, hospitalization in temporary ICUs was an independent risk factor associated with mortality.

show abstract

“…This classification was in part due to the several key mutations B.1.1.519 encodes including amino acid substitutions T478K, P681H, and T732A in the spike (S) protein, that may affect affinity to the SARS-CoV-2 receptor, human angiotensin I converting enzyme-2 (hACE-2). Notably, a study examining the clinical impact of B.1.1.519 infection in Mexico City found patients infected with B.1.1.519 displayed a significant increase in the severity of COVID-19 respiratory tract symptoms relative to patients infected with non-B.1.1.519 variants (Cedro-Tanda et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Founder effect contributes to the unique pattern of SARS-CoV-2 variant B.1.1.519 emergence in Alaska

Haan

Smith

DeRonde

et al. 2022

Preprint

View full text Add to dashboard Cite

Alaska is the largest geographic state in the United States with the lowest population density and a mix of urban centers and isolated rural communities. The differences in population dynamics in Alaska from the contiguous United States may have contributed to a unique pattern of emergence and spread of SARS-CoV-2 variants observed in early 2021. Here we examined 2,323 virus genomes from Alaska and 278,635 virus genomes from the contiguous United States collected between the first week of December 2020 through the last week of June 2021. We focused on this timeframe because of the notable emergence and spread of the SARS-CoV-2 lineage B.1.1.519 observed in Alaska. We found that this variant was consistently detected in Alaska from the end of January through June of 2021 with a peak prevalence in April of 77.9% unlike the rest of the United States with a peak prevalence of 4.6%. In Alaska, the earlier emergence of B.1.1.519 coincided with a later peak of Alpha (B.1.1.7) when compared to the rest of the United States. We also observed differences in the composition of lineages and variants over time between the two most populated regions of Alaska. Although there was a modest increase in COVID-19 cases during the peak incidence of B.1.1.519, it is difficult to disentangle how social dynamics conflated changes in COVID-19 during this time. We suggest that the viral characteristics, such as amino acid substitutions in the spike protein, and a founder effect likely contributed to the unique spread of B.1.1.519 in Alaska.

show abstract

The evolutionary landscape of SARS-CoV-2 variant B.1.1.519 and its clinical impact in Mexico City

Cited by 17 publications

References 52 publications

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

Outcomes in Temporary ICUs Versus Conventional ICUs: An Observational Cohort of Mechanically Ventilated Patients With COVID-19–Induced Acute Respiratory Distress Syndrome

Founder effect contributes to the unique pattern of SARS-CoV-2 variant B.1.1.519 emergence in Alaska

Contact Info

Product

Resources

About